The question is, will it beat amiodarone in the nonischemic group? Prospective economic and quality-of-life analyses of SCD-HeFT data will be reported at a future meeting, Lee said. Of the patients in ...
WARNING: The Thumbs up, thumbs down commentaries are freewheeling, sometimes contentious, always interesting discussions about the latest clinical trials affecting cardiologists.These discussions may ...
NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...
This new economic valuation of the societal and health care benefits of gene therapy to treat sickle cell disease (SCD) concludes the highly personalized treatment has potential to be cost effective ...
81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback